NCT03233711 2026-04-13
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Xiamen University
Shanghai Bovax Biotechnology Co., Ltd.
Beijing Health Guard Biotechnology, Inc